Drug Profile


Alternative Names: Femivia; Prasterone/Acolbifene

Latest Information Update: 04 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endoceutics
  • Class Antineoplastics; Hormonal replacements; Osteoporosis therapies; Small molecules; Testosterone congeners
  • Mechanism of Action Cell differentiation stimulants; Immunomodulators; Selective estrogen receptor modulators; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Breast cancer; Osteoporosis; Vasomotor symptoms

Highest Development Phases

  • Phase III Vasomotor symptoms
  • Research Breast cancer; Osteoporosis

Most Recent Events

  • 04 Dec 2015 Acolbifene/prasterone is still in phase III trials for Vasomotor symptoms in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top